Pediatric and Adult Translational Cancer Drug Discovery and Development Training Program (PACT-D3)

儿童和成人转化癌症药物发现和开发培训计划 (PACT-D3)

• 批准号: 10708526
• 负责人: David W Clapp
• 金额: $ 15.88万
• 依托单位: INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-09-01 至 2028-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10708526
• 关键词: Adult; Antineoplastic Agents; Childhood; Training Programs; drug development; drug discovery

Abstract This training program is unique for our institution, creating the next generation of basic and clinical investigators who focus their efforts on strategic and comprehensive drug discovery and development in cancer. This program capitalizes on a strong infrastructure and institutional commitment to the training of graduate student trainees for careers in pediatric and adult drug discovery and development. The addition of a pediatric cancer focus addresses an unmet need as well as a major focus of NCI as determined by the NCI's board of scientific advisors and the resulting Childhood Cancer Data (CCDI) initiative. The wealth of adult experience and pediatric researchers is uniquely being used in this T32 to develop novel approaches in pediatric drug discovery. There are no current NCI T32s with an emphasis on both pediatric and adult cancer drug discovery and development training. Cancer remains the leading cause of disease-related death in children. For the many children who experience relapses of their malignant solid tumors curative treatment options are scarce. The pediatric efforts will dovetail with the multi-institutional “Developmental and HyperActive Ras Tumor (DHART)” SPORE led by multi-PI Dr. Wade Clapp focusing on neurofibromatosis type 1 (NF1)—the most common human genetic cancer predisposition syndrome. Findings in this SPORE have led to new clinical trials for pediatric patients, and it is anticipated additional new drugs will need to be developed that is beyond the scope of the SPORE. In addition, the NIH/NICHD-funded P50, “Specialized Centers in Research in Pediatric Developmental Pharmacology” is using precision genomics strategies and in vivo modeling to design efficacious and safe combination therapies for relapsed solid tumors such as osteosarcoma and additional new targets for potential drug development are being identified. This highlights our focus and opportunity to identify new drug targets and develop new drugs specifically for pediatric patients. This program will be supported by collaborative efforts from other programs at the IU School of Medicine (IUSM) including the NCI designated IU Simon Comprehensive Cancer Center (IUSCCC); the Cancer Drug Discovery and Development (CDDD) center which is embedded in the IUSCCC Experimental and Developmental Therapeutics (EDT) program; the TaRget Engagement to Accelerate Therapy Development for Alzheimer's Disease (TREAT-AD) Center and the Indiana CTSI Preclinical Innovation “Think Tank” program. We will focus on graduate students as trainees, who will be recruited from two centralized programs that oversee graduate student recruitment and guide trainees in selecting mentors and home departments. These two programs are the Indiana BioMedical Gateway (IBMG) program, which enrolls ~36 graduate students per year and MSTP which enrolls ~10 per year. Eighteen mentors are intimately involved in this program and drug development efforts at the school. The goal of PACT-D3 is focused on grooming the next generation of diverse, basic, and translational researchers with interests in pediatric and adult cancer drug discovery and development.

抽象的 该培训计划对于我们机构来说是独一无二的，旨在培养下一代基础和临床研究人员 他们专注于癌症的战略性和综合性药物发现和开发。 利用强大的基础设施和机构承诺来培训研究生学员 儿科和成人药物发现和开发的职业生涯增加了儿科癌症重点。 解决未满足的需求以及 NCI 科学委员会确定的 NCI 的主要关注点 顾问和由此产生的儿童癌症数据 (CCDI) 倡议 丰富的成人经验和儿科知识。 研究人员在 T32 中被独特地用于开发儿科药物发现的新方法。 目前没有强调儿童和成人癌症药物发现和开发的 NCI T32 对于许多儿童来说，癌症仍然是疾病相关死亡的主要原因。 恶性实体瘤复发的儿科治疗方案很少。 将与由多机构领导的“发育性和过度活跃 Ras 肿瘤 (DHART)”SPORE 相配合 多位 PI Wade Clapp 博士专注于 1 型神经纤维瘤病 (NF1)——最常见的人类遗传癌症 该 SPORE 的发现引发了针对儿科患者的新临床试验，并且它是 预计需要开发超出 SPORE 范围的其他新药。 NIH/NICHD 资助的 P50，“儿科发育药理学研究专业中心” 使用精确基因组学策略和体内建模来设计有效且安全的联合疗法 针对骨肉瘤等复发性实体瘤以及潜在药物开发的其他新靶点 这凸显了我们确定新药物靶点和开发新药物的重点和机会。 该计划将得到其他项目的合作支持。 印第安纳大学医学院 (IUSM)，包括 NCI 指定的印第安纳大学西蒙综合癌症中心 (IUSCCC)；隶属于 IUSCCC 的癌症药物发现和开发 (CDDD) 中心 实验和发展治疗 (EDT) 计划；加速治疗的目标参与 阿尔茨海默病发展 (TREAT-AD) 中心和印第安纳州 CTSI 临床前创新“Think “Tank”计划将重点以研究生作为实习生，他们将从两个集中招募。 监督研究生招生并指导学员选择导师和家庭的计划 这两个项目是印第安纳生物医学网关 (IBMG) 项目，招收约 36 名学生。 每年招收 10 名研究生，MSTP 每年招收约 10 名导师。 该计划和学校的药物开发工作的目标是培养下一代。 一代对儿科和成人癌症药物感兴趣的多元化、基础和转化研究人员 发现和发展。